Pancreatic Cancer

Sep 20, 2022

AstraZeneca’s Danicopan Shows Positive Results in Phase III Trial Danicopan, an oral Factor D inhibitor developed by AstraZeneca, was expected to fail a phase II trial in rare kidney disease in 2020, but a new readout could revive the drug. Danicopan (ALXN2040) has demonstrated efficacy as an adjunct treatment f...

Sep 09, 2022

Treatment for pancreatic cancer patients is challenging and not well defined, especially for patients with disease progression or adverse events seen after initial treatment. Studies suggest that, after diagnosis, about 22% of pancreatic cancer patients, regardless of their clinical stage of cancer, receive no trea...

Oct 20, 2020

Full FDA Approval for Venclexta Combinations for Acute Myeloid Leukemia   The US FDA has granted its full approval to Venclexta (venetoclax) for newly diagnosed acute myeloid leukemia (AML) in adults 75 years or older who are unfit for intensive induction chemotherapies.  The approval is based on the res...

Jun 18, 2020

Lassen Therapeutics to create anti-IL-11 antibody for cancer and fibrosis Lassen Therapeutics is revealing USD 31 million from Frazier Healthcare Partners, Alta Venture and Longwood Fund and has an aim to create antibodies for cancer and fibrosis treatment. IL-11, a cytokine that plays a role in both disease are...

Feb 20, 2020

Incyte meets endpoint in the second pivotal atopic dermatitis clinical trial A second phase 3 trial of Incyte’s ruxolitinib cream in atopic dermatitis has hit its primary endpoint. The back-to-back pivotal successes irked Incyte to talk to regulators regarding upcoming of the JAK inhibitor to market. Ruxoliti...

Jun 25, 2019

FDA grants priority review to Zejula Niraparib (Zejula) received a priority review by the U.S. FDA, in response to a supplemental New Drug Application (sNDA) submitted by Tesaro. The drug, acquired by GlaxoSmithKline along with the drugmaker Tesaro for USD 5.1 Million, has an action date of October 24, 2019. T...

Apr 02, 2019

Selumetinib gets the U.S. Breakthrough Therapy Designation Selumetinib- an investigational drug, for the treatment of pediatric patients aged three years and above suffering from symptomatic and/or progressive, inoperable neurofibromatosis type 1 (NF1), plexiform neurofibromas (PN)- a rare genetic condition, has...

Sep 14, 2018

In the grueling quest for discovering more effective cancer treatment therapies, researchers every now and then come up with interesting breakthroughs, which flash rays of hope not only to the patients, but also for the drug manufacturers to capitalize upon the discoveries. A research team, at the Houston University...

Mar 15, 2017

Data from three cohorts of patients with early stage pancreatic ductal adenocarcinoma (PDAC) indicate that a two-protein biomarker panel, consisting of plasma tissue factor pathway inhibitor (TFPI) and tenascin-C (TNC-FN-III-C), as measured in plasma samples using an ELISA improves the prognostic value of CA 19-9. T...

Mar 15, 2017

Data from three cohorts of patients with early stage pancreatic ductal adenocarcinoma (PDAC) indicate that a two-protein biomarker panel, consisting of plasma tissue factor pathway inhibitor (TFPI) and tenascin-C (TNC-FN-III-C), as measured in plasma samples using an ELISA improves the prognostic value of CA 19-9. T...